

REMARKS

Reconsideration of this Application is respectfully requested. Applicants wish to thank Examiner Hobbs for her kind consideration and helpful suggestions during the Examiner Interview conducted on April 18, 2008. All of her suggestions are incorporated in the Amendment of the same date.

Applicants now submit this Supplemental Amendment with remarks in connection with the amendments set forth herein, and as a continuation of and supplement to those provided in Applicants' Amendment of April 18, 2008, for the Examiner's further consideration.

More specifically, in addition to matters attended to in Applicants' Amendment dated April 18, Applicants have undertaken to provide supplemental amendments to the Specification, without prejudice or disclaimer, to further comport with U.S. practice and, in so doing, to better define the invention without limiting effect.

With reference to the concentration of Enzyme D administered, according to paragraph d) in each of Claims 1 and 5 and as recited in the fifth full paragraph on page 7, such concentration is now correctly indicated, by way of Applicants' Amendment of April 18 (i.e., to Claims 1 and 5) and in the present Supplemental Amendment (i.e., to page 7 of the Specification), as being generally within a range of 7 U.I. and 9 U.I. rather than 5 U.I. and 7 U.I., also to better define the invention without limiting effect. Support for this range of constituents is found, for example, in the Specification on page 6, paragraph 1. Applicants respectfully state that no new matter has been added.


Pursuant to discussions with Examiner Hobbs including the Examiner Interview on April 18, 2008, Applicants reiterate their understanding that the Examiner has found

no references that, the Examiner asserts, could anticipate or render obvious Applicants' invention, as claimed.

Applicants respectfully submit that none of the cited references, whether taken alone or in any combination, disclose or suggest Applicants' invention, as claimed.

Applicants have made a good faith attempt to place this Application in condition for allowance. Favorable action is requested. If there is any further point requiring attention prior to allowance, the Examiner is asked to contact Applicants' counsel at (646) 265-1468.

Respectfully submitted,




Dated: April 25, 2008

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail, in an envelope with sufficient postage addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on April 25, 2008

Name Grant E. Pollack



Signature

Grant E. Pollack, Esq.

Registration No. 34,097

POLLACK, P.C.

The Chrysler Building

132 East 43rd Street, Suite 760

New York, New York 10017

Telephone: (646) 265-1468

Facsimile: (646) 253-1276

E-mail: gpollack@pollackpc.com

Attorney for Applicants